In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Sangamo Therapeutics Inc’s stock clocked out at $0.54, down -0.30% from its previous closing price of $0.54. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 2.3 million shares were traded. SGMO stock price reached its highest trading level at $0.5651 during the session, while it also had its lowest trading level at $0.535.
Ratios:
To gain a deeper understanding of SGMO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.05. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 162440112 and an Enterprise Value of 147557392. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.99 while its Price-to-Book (P/B) ratio in mrq is 7.49. Its current Enterprise Value per Revenue stands at 1.806 whereas that against EBITDA is -2.532.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.21, which has changed by -0.3493976 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 2.21%, while the 200-Day Moving Average is calculated to be -47.32%.
Shares Statistics:
It appears that SGMO traded 5.84M shares on average per day over the past three months and 5401030 shares per day over the past ten days. A total of 301.71M shares are outstanding, with a floating share count of 292.13M. Insiders hold about 3.17% of the company’s shares, while institutions hold 17.09% stake in the company. Shares short for SGMO as of 1755216000 were 15958387 with a Short Ratio of 2.73, compared to 1752537600 on 23364456. Therefore, it implies a Short% of Shares Outstanding of 15958387 and a Short% of Float of 5.3400002.
Earnings Estimates
A detailed examination of Sangamo Therapeutics Inc (SGMO) is currently in progress, with 3 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.37 and -$0.43 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $34.4M. It ranges from a high estimate of $100M to a low estimate of $4M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $49.41M
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $124.7M, while the lowest revenue estimate was $34.7M, resulting in an average revenue estimate of $72.3M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $48.3M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
